We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Nanomedical Applications Global Market Worth $3.8 Billion by 2013

By LabMedica International staff writers
Posted on 03 Oct 2008
According to a new technical market research report, the global medical market for nanotechnology applications generated US$1.7 billion in 2007. More...
This is expected to increase to $1.9 billion in 2008, and $3.8 billion in 2013 for a compound annual growth rate (CAGR) of 14.9%. Furthermore, this market has the potential to reach $9.4 billion in 2018 at a CAGR of 19.9%.

According to BCC Research (Wellesley, MA, USA), a marketing research company, the market is broken down into the categories of nanoparticles, other nanostructured materials, and nanotools/nanodevices. Of these, the nanoparticles segment has the largest share of the market. Valued at $1.6 billion in 2007, this segment should increase at a CAGR of 13.4% to reach $1.8 billion in 2008 and $3.4 billion in 2013. Nanoparticles could potentially see $7.9 billion in revenue in 2018 with a CAGR of 18.6%.

Other nanostructured materials represent the next largest, and fastest growing, segment. Nanostructured materials generated $36.5 million in 2007 and an estimated $45.1 million in 2008. This should increase to $304.7 million in 2013 for a CAGR of 46.5%. This segment has the potential to reach $1.1 billion in 2018 at a CAGR of 29.4%.

Nanotools and nanodevices have the smallest share of the market, worth $30.5 million in 2007. This is expected to grow at a CAGR of 17.8% to reach $34.2 million in 2008 and $77.6 million in 2013. There is a potential for this segment to generate $287.5 million in 2018 at a CAGR of 29.9%.

Pharmaceutical applications currently dominate the market, according to BCC, accounting for nearly 90% of revenue in 2007, and this trend is expected to continue through 2008. This segment is expected to decrease to less than 70% of the market by 2013 and potentially near 50% of the market by 2018. Nanotechnology applications for medical research and medical devices are both expected to significantly gain in market share, potentially reaching 20% each by 2018.

BCC's market analysis delivers market research reports, newsletters, and conferences that provide companies with the insights needed to make intelligent and strategic business decisions.

Related Links:
BCC Research



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.